Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review
Open accessThe DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index; 53 of the 224 sources its claims cite were checked for support.
Abstract
Background/Objectives: Incretin-based medications have transformed obesity management by enabling substantial body weight reduction. However, the rapid and pronounced loss of body mass necessitates a comprehensive, multidisciplinary approach incorporating nutritional and physical activity strategies to preserve lean mass, optimize functional outcomes, and prevent long-term complications. This narrative review provides a critical overview of this emerging clinical concern, which is expected to gain increasing relevance in the coming years. Methods: A literature review was conducted up to 31 October 2025, focusing on studies addressing nutritional, physical activity, and adjunctive interventions in adults with obesity treated with incretin-based medications. Results: Incretin-based agents induce significant weight loss, comparable to bariatric surgery, predominantly targeting adipose tissue. Nevertheless, these medications also cause rapid reductions in muscle and bone mass, often accompanied by nutrient deficiencies, which may compromise metabolic health and physical function. Tailored nutritional strategies—including hypocaloric diets enriched in protein and fiber, as well as amino acid, vitamin, and mineral supplementation—are critical to preserve lean mass and support sustained weight maintenance. Concurrently, structured, supervised physical activity, encompassing aerobics, resistance, and strength training, mitigates muscle loss and enhances functional capacity. Emerging pharmacological agents designed to promote adipose tissue reduction while preserving lean mass, as well as interventions targeting gut microbiota modulation, may represent promising adjunctive strategies to optimize long-term outcomes further. Conclusions: While incretin-based medications produce substantial weight loss, their impact on lean mass underscores the necessity of integrating personalized nutrition, supplementation, and structured exercise to preserve muscle, prevent malnutrition, and optimize long-term health and obesity outcomes.
Overview
CoChat Summary
TL;DR
Incretin-based medications produce substantial weight loss but also reduce lean mass, bone mass, and micronutrient status, requiring personalized nutrition and structured physical activity to preserve muscle and function. This narrative review synthesizes evidence from trials, supplementation studies, and bariatric-surgery paradigms to outline dietary, supplement, and exercise strategies for adults with obesity on these agents.
Key findings
- Incretin-based agents induce weight loss comparable to bariatric surgery, but a meta-analysis of RCTs found approximately 25% of total weight loss is attributable to lean mass loss, with no significant change in relative lean mass.
- In a STEP-1 DXA subset, 40% of total weight loss (6.92 kg out of 17.32 kg) was attributable to lean mass reduction, corresponding to 13.2% of baseline total lean mass; in a SURMOUNT-1 DXA substudy, tirzepatide reduced fat mass by 33.9% and lean mass by 10.9%, versus 5.3% and 2.6% with placebo.
- Nutritional strategies include hypocaloric diets enriched in protein and fiber, with suggested protein intakes of approximately 1.25–1.5 times the RDA, at least ~25–30 g protein per meal, or 1.5 g/kg fat-free mass per day; supplementation with amino acids, vitamin D, B vitamins, and minerals may be needed.
- In the Lundgren et al. RCT, combining exercise with liraglutide produced mean weight loss of 9.5 kg over one year, superior to exercise alone (4.1 kg) and liraglutide alone (6.8 kg); after treatment cessation, weight regain was 6.0 kg greater after stopping liraglutide than after stopping supervised exercise.
Methods
- Narrative review with a MEDLINE (PubMed) search conducted from February to October 2025, limited to English-language papers published within the last ten years.
- Search terms covered physical activity, nutrition, diet, supplements, lean mass loss, and lean mass preservation with anti-obesity medications.
- Eligible studies included systematic reviews, narrative reviews, meta-analyses, observational studies, RCTs, and clinical practice guidelines in adults with obesity; animal studies, participants ≤18 years, editorials, letters, case reports, book chapters, and commentaries were excluded; two authors independently assessed search and eligibility.
Limitations
- Stated: the paper notes a lack of a comprehensive, evidence-based review specifically addressing nutritional needs of patients treated with the most recent and effective anti-obesity medications, and states that official guidelines are absent.
- Stated: data are insufficient to determine the correct amount of protein needed to preserve fat-free mass after bariatric surgery, and evidence on gut microbiota changes is described as controversial with causality unresolved.
- Evident from the text: as a narrative review, it does not report a systematic protocol, risk-of-bias assessment, or quantitative synthesis; findings are drawn from heterogeneous study designs, populations, and interventions, and many nutritional/exercise recommendations are extrapolated from bariatric surgery or general obesity literature rather than from trials specifically in incretin-treated patients.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
31 Valid · 3 Not valid · 128 Not checked · 18 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Through these mechanisms, incretin-based medications promote body weight reduction primarily by targeting AT [6].”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 1. Introduction
What the sources say
- Partly supportedcites [6] De Fano, M., Malara, M., Vermigli, C., and Murdolo, G. (2024). Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance. Int. J. Mol. Sci., 25. sourceExperimental — accuracy not yet measured
Our copy does attribute some of the weight-loss effect to adipose-level actions — Section 6.1 (WAT/GLP-1R in adipocytes and SVF) states that supraphysiological GLP-1 RA concentrations have 'anorexigenic and lipolytic effects that, ultimately, contribute to weight loss', and Section 6.3 reports preclinical evidence that GLP-1 weight loss involves increased energy expenditure via BAT thermogenesis. However, the same Section 6.3 passage says the main mechanism is 'not only by decreasing appetite and hunger but also by increasing energy expenditure', and Section 3 ties the body-weight impact to GLP-1R in brainstem and hypothalamic appetite/regulation nuclei — so the source does not say weight reduction occurs 'primarily' by targeting AT. On the contrary, the Abstract and Section 10 frame AT as only a 'novel'/'potential' target for which the authors propose 'a potential scientific rationale', noting that adipose-specific drugs 'warrants further investigations'; the claim therefore upgrades a hedged hypothesis into a stated primary mechanism. (LLM, conf=0.78)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Semaglutide 2.4 mg weekly, evaluated in the STEP program, consistently produced 14.9–17.4% WL [19]”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
What the sources say
- Partly supportedcites [19] Garvey, 2023, Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2): A Double-Blind, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial, Lancet sourceExperimental — accuracy not yet measured
The Discussion identifies semaglutide 2.4 mg as a treatment evaluated in STEP 2 and STEP 5 and discusses its effect on body weight. Neither the Discussion nor the Research in context passage reports the claimed 14.9–17.4% weight-loss range or establishes that it occurred consistently across the STEP program (page numbers unavailable). (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Semaglutide 2.4 mg weekly reduced major CV events in individuals with preexisting CV disease (SELECT trial) [24]”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
What the sources say
- Supportedcites [24] Lincoff, 2023, Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, N. Engl. J. Med. source
The Conclusions report that, in the SELECT trial, weekly subcutaneous semaglutide 2.4 mg reduced the incidence of the composite cardiovascular endpoint compared with placebo. The enrolled patients had preexisting cardiovascular disease, overweight or obesity, and no diabetes. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Additionally, other preclinical studies suggest that GLP-1 RAs may promote skeletal muscle remodeling through changes in fiber type and energy substrate utilization [12].”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 1. Introduction
What the sources say
- Supportedcites [12] Wu, 2022, GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway, Biochim. Biophys. Acta Mol. Cell Res. source
Section 2.7.2 identifies exendin-4 as a GLP-1 receptor agonist used in the paper’s cell experiments. The Discussion reports that exendin-4 increased glucose uptake and slow-twitch fiber marker expression in myotubes, supporting the hedged claim about preclinical muscle remodeling and energy substrate use. Page numbers were unavailable in our copy. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the SCALE Obesity and Prediabetes trial, liraglutide 3.0 mg daily combined with lifestyle intervention resulted in a mean WL of 8.4 ± 7.3 kg over 56 weeks, significantly greater than placebo (2.8 ± 6.5 kg) [18].”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
What the sources say
- Supportedcites [18] Astrup, 2015, A Randomized, Controlled Trial of 3.0 Mg of Liraglutide in Weight Management, N. Engl. J. Med. source
The Methods (p. 1) identify the SCALE Obesity and Prediabetes trial as a 56-week comparison of once-daily 3.0 mg liraglutide and placebo, with lifestyle counseling in both groups. The Results (p. 1) report weight losses of 8.4±7.3 kg and 2.8±6.5 kg, respectively, with a significant between-group difference (P<0.001). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
80 more claims · 12 with their cited sources checked
Create a free account to see all 180 claims and to verify the 171 references still open.
- It may state two separate claims as one. 82
- Probably not a substantial claim. 23
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent GLP-1-specific narrative consensus extends these recommendations to patients receiving incretin-based pharmacotherapy [71].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [71]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“From weeks 36 to 88, weight change was −5.5% for tirzepatide compared to −14.0% for placebo (difference −19.4%, p < 0.001).”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.5. PA in Obese People Treated with Incretin-Based Medications
Reported -19.4 · recomputed 8.5
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
“Semaglutide 2.4 mg weekly, evaluated in the STEP program, consistently produced 14.9–17.4% WL [19]”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > References
“19. Garvey W.T. Frias J.P. Jastreboff A.M. Le Roux C.W. Sattar N. Aizenberg D. Mao H. Zhang S. Ahmad N.N. Bunck M.C. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
“In SURMOUNT-1, tirzepatide 15 mg weekly induced a mean weight reduction of up to −20.9% at 72 weeks in individuals with obesity and without T2DM, compared with −3.1% with placebo [21].”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > References
“21. Rubino D.M. Greenway F.L. Khalid U. O’Neil P.M. Rosenstock J. Sørrig R. Wadden T.A. Wizert A. Garvey T.W. STEP 8 Investigators Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.5. PA in Obese People Treated with Incretin-Based Medications
“4 diets with different percentages of protein, fat, and carbohydrates, respectively: 20, 15, and 65%; 20, 25, and 55%; 40, 15, and 45%; and 40, 25, and 35%.”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.5. PA in Obese People Treated with Incretin-Based Medications
“It was similar in participants assigned to a diet with 25% protein or 15% protein (3.6 and 3.0 kg, respectively; p = 0.22); the same in those assigned to a diet with 40% or 20% fat”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > 3. Results > 3.1. Evidence from Clinical Trials on GLP-1 RAs and Tirzepatide in Obesity: Effects on Weight Reduction and the Amelioration of Obesity-Related Organ Damage
“In SURMOUNT-2, participants with obesity and T2DM experienced WL of up to −14.7% [22].”
§ Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review > References
“22. Jastreboff A.M. Aronne L.J. Ahmad N.N. Wharton S. Connery L. Alves B. Kiyosue A. Zhang S. Liu B. Bunck M.C. Tirzepatide Once Weekly for the Treatment of Obesity”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657 · cited 1×
“To prevent weight gain and achieve health improvements, the WHO [120] and the American College of Sports Medicine [118] guidelines recommend five or more days per week of moderate-intensity PA (150–250 min/week), plus almost two days/week of strength EXE.”
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“In SURMOUNT-2, participants with obesity and T2DM experienced WL of up to − 14.7% [22].”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
de Lorgeril, M., Salen, P., Martin, J.-L., Monjaud, I., Delaye, J., & Mamelle, N. (1999) · Circulation · doi:10.1161/01.cir.99.6.779 · Cited by 2,910
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
DONNELLY, J. E., BLAIR, S. N., JAKICIC, J. M., MANORE, M. M., RANKIN, J. W., & SMITH, B. K. (2009) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181949333 · Cited by 2,658
Weight Loss with a Low-Carbohydrate, Mediterranean, or Low-Fat Diet
Shai, I., Schwarzfuchs, D., Henkin, Y., Shahar, D. R., Witkow, S., Greenberg, I., Golan, R., Fraser, D., Bolotin, A., Vardi, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708681 · Cited by 2,143
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 1×
“Evidence has consistently demonstrated their benefits in individuals with obesity, including substantial WL (often exceeding the 10% WL achieved with intensive lifestyle interventions), improved quality of life (QoL), and reductions in obesity-related organ damage [7,8].”
Comparison of Weight-Loss Diets with Different Compositions of Fat, Protein, and Carbohydrates
Sacks, F. M., Bray, G. A., Carey, V. J., Smith, S. R., Ryan, D. H., Anton, S. D., McManus, K., Champagne, C. M., Bishop, L. M., Laranjo, N., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804748 · Cited by 1,966 · cited 4×
“…in terms of WL and improved metabolic parameters are significant, their influence on eating patterns and dietary quality has not been widely reported, and an unbalanced nutritional intake accompanied by a calorie deficit can lead to macro/micronutrient deficiencies and loss of LM [59,63,73,152].”
InfluentialDefinition and diagnostic criteria of clinical obesity
Rubino, F., Cummings, D. E., Eckel, R. H., Cohen, R. V., Wilding, J. P. H., Brown, W. A., Stanford, F. C., Batterham, R. L., Farooqi, I. S., Farpour-Lambert, N. J., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00316-4 · Cited by 1,811
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 2×
“…CV disease (SELECT trial) [24], improved physical function in adult heart failure with preserved ejection fraction (HFpEF) (STEP-HFpEF trial) [25], reduced pain and analgesics use in knee osteoarthritis (STEP-9 trial) [26], and demonstrated histological benefits in metabolic…”
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 1×
“Nausea, vomiting, diarrhea, and constipation are common, particularly during treatment initiation or dose escalation, though they are generally mild, transient, and resolve spontaneously even with ongoing therapy [15].”
Obesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174 · cited 1×
“In a phase 2 RCT, weekly doses of 12 mg of retatrutide induced over 24% WL in adults with obesity [148].”
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413258 · Cited by 1,115 · cited 1×
“…use in knee osteoarthritis (STEP-9 trial) [26], and demonstrated histological benefits in metabolic dysfunction-associated steatohepatitis (MASH) (ESSENCE trial) [27], leading to Food and Drug Administration (FDA) approval for the treatment of MASH with moderate-to-advanced fibrosis [28].”
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
Packer, M., Zile, M. R., Kramer, C. M., Baum, S. J., Litwin, S. E., Menon, V., Ge, J., Weerakkody, G. J., Ou, Y., Bunck, M. C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410027 · Cited by 1,009
Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401943 · Cited by 1,005
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Malhotra, A., Grunstein, R. R., Fietze, I., Weaver, T. E., Redline, S., Azarbarzin, A., Sands, S. A., Schwab, R. J., Dunn, J. P., Chakladar, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404881 · Cited by 871
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860 · cited 1×
“Both the STEP-4 [128] and SURMOUNT-4 [129] studies showed that after 20 weeks of pharmacological treatment with semaglutide and after 36 weeks with tirzepatide, respectively, people with obesity tended to regain weight if the pharmacological treatment was stopped.”
Garvey, W. T., Frias, J. P., Jastreboff, A. M., le Roux, C. W., Sattar, N., Aizenberg, D., Mao, H., Zhang, S., Ahmad, N. N., Bunck, M. C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01200-x · Cited by 792
on behalf of the NN8022-1807 Investigators, Astrup, A., Carraro, R., Finer, N., Harper, A., Kunesova, M., Lean, M. E. J., Niskanen, L., Rasmussen, M. F., Rissanen, A., et al. (2012) · International Journal of Obesity · doi:10.1038/ijo.2011.158 · Cited by 757 · cited 1×
“…to liraglutide, Astrup et al. evaluated body composition in 72 individuals with obesity using dual-energy X-ray Absorptiometry (DXA) following 20 weeks of treat-ment at doses ranging from 1.2 to 3.0 mg, reporting FM reductions of approximately 13–16% alongside LM losses of approximately 1–3% [34].”
InfluentialTirzepatide as Compared with Semaglutide for the Treatment of Obesity
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2416394 · Cited by 634 · cited 1×
“%) and waist circumference reduction [23].”
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Lundgren, J. R., Janus, C., Jensen, S. B. K., Juhl, C. R., Olsen, L. M., Christensen, R. M., Svane, M. S., Bandholm, T., Bojsen-Møller, K. N., Blond, M. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028198 · Cited by 536 · cited 2×
“Some authors have shown that AOMs are more effective in WL than the lifestyle approach alone [62,125]; for example, Wadden et al. reported that WL induced by lifestyle modification is approximately 5–10% [62].”
The role of protein in weight loss and maintenance
Leidy, H. J., Clifton, P. M., Astrup, A., Wycherley, T. P., Westerterp-Plantenga, M. S., Luscombe-Marsh, N. D., Woods, S. C., & Mattes, R. D. (2015) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.084038 · Cited by 475
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463 · cited 1×
“GLP-1 RAs are thought to induce weight reduction through actions in central and peripheral neuroendocrine systems involved in the regulation of food intake [3].”
Neufingerl, N., & Eilander, A. (2021) · Nutrients · doi:10.3390/nu14010029 · Cited by 455
Preserving Healthy Muscle during Weight Loss
Cava, E., Yeat, N. C., & Mittendorfer, B. (2017) · Advances in Nutrition · doi:10.3945/an.116.014506 · Cited by 452 · cited 2×
“…to the American College of Sports Medicine, people with obesity undergoing WL treatment should consume approximately 1.25–1.5 times the Recommended Dietary Allowance (RDA) for daily protein intake (for athletes > 1.5), with at least ∼ 25–30 g of protein per meal [83,84] to limit muscle mass loss.”
InfluentialOnce-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Bliddal, H., Bays, H., Czernichow, S., Uddén Hemmingsson, J., Hjelmesæth, J., Hoffmann Morville, T., Koroleva, A., Skov Neergaard, J., Vélez Sánchez, P., Wharton, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2403664 · Cited by 440 · cited 1×
“…failure with preserved ejection fraction (HFpEF) (STEP-HFpEF trial) [25], reduced pain and analgesics use in knee osteoarthritis (STEP-9 trial) [26], and demonstrated histological benefits in metabolic dysfunction-associated steatohepatitis (MASH) (ESSENCE trial) [27], leading to Food and Drug…”
Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01185-6 · Cited by 431
Zinc deficiency and cellular oxidative stress: Prognostic implications in cardiovascular diseases
Choi, S., Liu, X., & Pan, Z. (2018) · Acta Pharmacologica Sinica · doi:10.1038/aps.2018.25 · Cited by 397 · cited 1×
“The association between zinc deficiency and the development of cardiovascular diseases (CVDs) has been supported by numerous studies [96].”
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Bellicha, A., van Baak, M. A., Battista, F., Beaulieu, K., Blundell, J. E., Busetto, L., Carraça, E. V., Dicker, D., Encantado, J., Ermolao, A., et al. (2021) · Obesity Reviews · doi:10.1111/obr.13256 · Cited by 375 · cited 3×
“Independent of the characteristics of PA after BS, it could enhance weight loss, muscle strength, and CRF [54–56].”
McManus, K., Antinoro, L., & Sacks, F. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801796 · Cited by 353
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332 · cited 1×
“A substantial pipeline of incretin-based pharmacotherapies is currently in development, aiming to further enhance efficacy and safety profiles [16].”
Semaglutide for the treatment of overweight and obesity: A review
Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14863 · Cited by 265
Evidence-based European recommendations for the dietary management of diabetes
The Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD), Aas, A.-M., Axelsen, M., Churuangsuk, C., Hermansen, K., Kendall, C. W. C., Kahleova, H., Khan, T., Lean, M. E. J., Mann, J. I., et al. (2023) · Diabetologia · doi:10.1007/s00125-023-05894-8 · Cited by 262
Sofi, F., Dinu, M., Pagliai, G., Cesari, F., Gori, A. M., Sereni, A., Becatti, M., Fiorillo, C., Marcucci, R., & Casini, A. (2018) · Circulation · doi:10.1161/circulationaha.117.030088 · Cited by 257
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Garvey, W. T., Blüher, M., Osorto Contreras, C. K., Davies, M. J., Winning Lehmann, E., Pietiläinen, K. H., Rubino, D., Sbraccia, P., Wadden, T., Zeuthen, N., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502081 · Cited by 238 · cited 2×
“The results from REDEFINE-1 and REDEFINE-2, demonstrated the efficacy of cagrisema, both in obese people with T2DM and those without T2DM [144,145].”
Nuijten, M. A. H., Eijsvogels, T. M. H., Monpellier, V. M., Janssen, I. M. C., Hazebroek, E. J., & Hopman, M. T. E. (2022) · Obesity Reviews · doi:10.1111/obr.13370 · Cited by 236
Iron Metabolism in Obesity and Metabolic Syndrome
González-Domínguez, Á., Visiedo-García, F. M., Domínguez-Riscart, J., González-Domínguez, R., Mateos, R. M., & Lechuga-Sancho, A. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155529 · Cited by 227
Willoughby, D., Hewlings, S., & Kalman, D. (2018) · Nutrients · doi:10.3390/nu10121876 · Cited by 221 · cited 2×
“Significant WL has been demonstrated with the use of green coffee, green tea, α -Lipoic Acid, cocoa, and chitosan [102,104–106].”
Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102475 · Cited by 207 · cited 2×
“Higher proportions of participants achieved significant WL thresholds: 70.9% lost ≥ 10%, 55.6% lost ≥ 15%, and 38.5% lost ≥ 20% with semaglutide, compared to 25.6%, 12.0%, and 6.0% with liraglutide, respectively (all p 0.001) [126].”
InfluentialKwok, C. S., Umar, S., Myint, P. K., Mamas, M. A., & Loke, Y. K. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.07.080 · Cited by 205 · cited 1×
“In this context, vegetarian or vegan diets, known for their wide range of health benefits, such as reduction in body weight, cholesterol, and incidence of T2DM [69,70], should be carefully planned.”
Borner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202 · cited 1×
“…from the FDA Adverse Event Reporting System indicate a lower incidence of nausea and vomiting, potentially due to GIP receptor-mediated neuronal inhibition in the area postrema [149,150], whereas constipation appears more frequent, with the underlying mechanisms yet to be fully elucidated [151].”
Iepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1176 · Cited by 193
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Wharton, S., Aronne, L. J., Stefanski, A., Alfaris, N. F., Ciudin, A., Yokote, K., Halpern, B., Shukla, A. P., Zhou, C., Macpherson, L., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2511774 · Cited by 189
Malnutrition in Obesity: Is It Possible?
Kobylińska, M., Antosik, K., Decyk, A., & Kurowska, K. (2022) · Obesity Facts · doi:10.1159/000519503 · Cited by 186
Look, M., Dunn, J. P., Kushner, R. F., Cao, D., Harris, C., Gibble, T. H., Stefanski, A., & Griffin, R. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16275 · Cited by 181 · cited 1×
“More recent evidence from a DXA sub-study of SURMOUNT-1, involving 160 participants demonstrated that tirzepatide induced reductions in FM and LM of 33.9% and 10.9%, respectively, compared with 5.3% and 2.6% in the placebo group [40].”
InfluentialLinge, J., Birkenfeld, A. L., & Neeland, I. J. (2024) · Circulation · doi:10.1161/circulationaha.124.067676 · Cited by 180
Richard, J. E., Anderberg, R. H., Göteson, A., Gribble, F. M., Reimann, F., & Skibicka, K. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119034 · Cited by 168 · cited 1×
“They also stimulate anorexigenic and suppress orexigenic signaling within the hypothalamus and modulate the mesolimbic system, collectively reducing the hedonic drive to eat [4].”
A Clinician's Guide to Healthy Eating for Cardiovascular Disease Prevention
Pallazola, V. A., Davis, D. M., Whelton, S. P., Cardoso, R. N., Latina, J. M., Michos, E. D., Sarkar, S., Blumenthal, R. S., Arnett, D. K., Stone, N. J., et al. (2019) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2019.05.001 · Cited by 158
Strategies for minimizing muscle loss during use of incretin‐mimetic drugs for treatment of obesity
Mechanick, J. I., Butsch, W. S., Christensen, S. M., Hamdy, O., Li, Z., Prado, C. M., & Heymsfield, S. B. (2025) · Obesity Reviews · doi:10.1111/obr.13841 · Cited by 149 · cited 2×
“Beyond macronutrient adeguacy, hypocaloric dietary strategies implemented during pharmacological therapy may increase the risk of micronutrients deficiencies, which are critical for maintaining muscle mass and function [82].”
Mechanisms of vitamin D action in skeletal muscle
Montenegro, K. R., Cruzat, V., Carlessi, R., & Newsholme, P. (2019) · Nutrition Research Reviews · doi:10.1017/s0954422419000064 · Cited by 147
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Davies, M. J., Bajaj, H. S., Broholm, C., Eliasen, A., Garvey, W. T., le Roux, C. W., Lingvay, I., Lyndgaard, C. B., Rosenstock, J., & Pedersen, S. D. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502082 · Cited by 143
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142 · cited 2×
“It is essential to note that age-related decreases in muscle mass average 0.47% and 0.37% per year in men and women, respectively [33].”
InfluentialOral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2500969 · Cited by 142 · cited 1×
“More recently, oral semaglutide 25 mg has been shown to induce a 13.6% WL after 71 weeks in obese individuals with T2DM [141].”
InfluentialNutritional considerations with antiobesity medications
Almandoz, J. P., Wadden, T. A., Tewksbury, C., Apovian, C. M., Fitch, A., Ard, J. D., Li, Z., Richards, J., Butsch, W. S., Jouravskaya, I., et al. (2024) · Obesity · doi:10.1002/oby.24067 · Cited by 134 · cited 6×
“The risk is further amplified by the appetite suppression commonly observed during AOM treatment [68,74].”
InfluentialOrforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes
Rosenstock, J., Hsia, S., Nevarez Ruiz, L., Eyde, S., Cox, D., Wu, W.-S., Liu, R., Li, J., Fernández Landó, L., Denning, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2505669 · Cited by 132
Khadra, D., Itani, L., Tannir, H., Kreidieh, D., Masri, D. E., & Ghoch, M. E. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i5.311 · Cited by 130 · cited 1×
“While AT loss is clinically desirable, preservation of fat-free mass (FFM)—particularly muscle and bone—is critical to avoid sarcopenic obesity (SO), a condition affecting approximately 42–43% of individuals with obesity and often associated with adverse outcomes [9].”
Wadden, T. A., Chao, A. M., Moore, M., Tronieri, J. S., Gilden, A., Amaro, A., Leonard, S., & Jakicic, J. M. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00534-z · Cited by 129 · cited 7×
“Some authors have shown that AOMs are more effective in WL than the lifestyle approach alone [62,125]; for example, Wadden et al. reported that WL induced by lifestyle modification is approximately 5–10% [62].”
InfluentialAroda, V. R., Aberle, J., Bardtrum, L., Christiansen, E., Knop, F. K., Gabery, S., Pedersen, S. D., & Buse, J. B. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01127-3 · Cited by 126
Verreijen, A. M., Engberink, M. F., Memelink, R. G., van der Plas, S. E., Visser, M., & Weijs, P. J. M. (2017) · Nutrition Journal · doi:10.1186/s12937-017-0229-6 · Cited by 121
Hansen, M. S., Wölfel, E. M., Jeromdesella, S., Møller, J.-J. K., Ejersted, C., Jørgensen, N. R., Eastell, R., Hansen, S. G., & Frost, M. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102624 · Cited by 115
Once-monthly maridebart cafraglutide for the treatment of obesity—a phase 2 trial
Jastreboff, A. M., Ryan, D. H., Bays, H. E., Ebeling, P. R., Mackowski, M. G., Philipose, N., Ross, L., Liu, Y., Burns, C. E., Abbasi, S. A., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2504214 · Cited by 110 · cited 1×
“Similarly, maridebart carfraglutide, known as MariTide, a long-acting peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism, achieved 12.3–16.2% WL after 52 weeks in obese participants with slightly lower reductions in individuals with T2DM [146].”
InfluentialNew horizons. A new paradigm for treating to target with second-generation obesity medications
Garvey, W. T. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab848 · Cited by 110
Wilding, J. P. H., Batterham, R. L., Calanna, S., Van Gaal, L. F., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wharton, S., Yokote, K., Zeuthen, N., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab048.030 · Cited by 107
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
GLP-1 regulates exercise endurance and skeletal muscle remodeling via GLP-1R/AMPK pathway
Wu, L., Zhou, M., Li, T., Dong, N., Yi, L., Zhang, Q., & Mi, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119300 · Cited by 101 · cited 1×
“Additionally, other preclinical studies suggest that GLP-1 RAs may promote skeletal muscle remodeling through changes in fiber type and energy substrate utilization [12].”
GLP-1RA Liraglutide and Semaglutide Improves Obesity-Induced Muscle Atrophy via SIRT1 Pathway
Xiang, J., Qin, L., Zhong, J., Xia, N., & Liang, Y. (2023) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s425642 · Cited by 100
Miketinas, D. C., Bray, G. A., Beyl, R. A., Ryan, D. H., Sacks, F. M., & Champagne, C. M. (2019) · The Journal of Nutrition · doi:10.1093/jn/nxz117 · Cited by 99
Iron Deficiency in Obesity and after Bariatric Surgery
Bjørklund, G., Peana, M., Pivina, L., Dosa, A., Aaseth, J., Semenova, Y., Chirumbolo, S., Medici, S., Dadar, M., & Costea, D.-O. (2021) · Biomolecules · doi:10.3390/biom11050613 · Cited by 99
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review
Gofron, K. K., Wasilewski, A., & Małgorzewicz, S. (2025) · Nutrients · doi:10.3390/nu17081303 · Cited by 90
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
Tabesh, M. R., Eghtesadi, M., Abolhasani, M., Maleklou, F., Ejtehadi, F., & Alizadeh, Z. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06703-2 · Cited by 78
Rabiei, S., Hedayati, M., Rashidkhani, B., Saadat, N., & Shakerhossini, R. (2019) · Journal of Dietary Supplements · doi:10.1080/19390211.2018.1455788 · Cited by 76 · cited 1×
“Dietary interventions, particularly those targeting the relationship between macronu-trients and microbiome, can affect postprandial GLP-1 secretion but cannot replace pharmacological treatments [114].”
Orsso, C. E., Montes‐Ibarra, M., Findlay, M., van der Meij, B. S., de van der Schueren, M. A. E., Landi, F., Laviano, A., & Prado, C. M. (2022) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12954 · Cited by 73
Alissou, M., Demangeat, T., Folope, V., Van Elslande, H., Lelandais, H., Blanchemaison, J., Cailleaux, P., Guney, S., Aupetit, A., Aubourg, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70141 · Cited by 72
Ito, M. K., Gonçalves, V. S. S., Faria, S. L. C. M., Moizé, V., Porporatti, A. L., Guerra, E. N. S., De Luca Canto, G., & de Carvalho, K. M. B. (2017) · Obesity Surgery · doi:10.1007/s11695-016-2453-0 · Cited by 69 · cited 1×
“To date, literary data are not significant to determine the correct amount of protein that must be consumed to preserve FFM after BS, and probably the general indication of consuming at least 60 g of protein a day is not sufficient to counterbalance FFM loss [47,48].”
Johnson, B., Milstead, M., Thomas, O., McGlasson, T., Green, L., Kreider, R., & Jones, R. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1566498 · Cited by 64 · cited 5×
“AOMs cause rapid and significant weight loss, higher and faster than traditional weight loss by diet and exercise, and offer a real and valid alternative to BS [66].”
InfluentialBarriers and Motivators to Weight Loss in People With Obesity
Binsaeed, B. S., Aljohani, F. G., Alsobiai, F. F. H., Alraddadi, M., Alrehaili, A. A., Alnahdi, B. S., Almotairi, F. S., Jumah, M. A., & Alrehaili, A. T. (2023) · Cureus · doi:10.7759/cureus.49040 · Cited by 64
Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
Nichele, S., Phillips, S. M., & Boaventura, B. C. B. (2022) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2021-0806 · Cited by 61 · cited 1×
“Recently, it has been shown that plant-based proteins can stimulate muscle protein synthesis [88].”
Nutritional Deficiencies Before and After Bariatric Surgery: Prevention and Treatment
Argyrakopoulou, G., Konstantinidou, S. M., Dalamaga, Μ., & Kokkinos, A. D. (2022) · Current Nutrition Reports · doi:10.1007/s13668-022-00400-9 · Cited by 60
Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss
Reiss, A. B., Gulkarov, S., Lau, R., Klek, S. P., Srivastava, A., Renna, H. A., & De Leon, J. (2025) · Biomolecules · doi:10.3390/biom15030408 · Cited by 58
Scott Butsch, W., Sulo, S., Chang, A. T., Kim, J. A., Kerr, K. W., Williams, D. R., Hegazi, R., Panchalingam, T., Goates, S., & Heymsfield, S. B. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100186 · Cited by 58 · cited 2×
“…in terms of WL and improved metabolic parameters are significant, their influence on eating patterns and dietary quality has not been widely reported, and an unbalanced nutritional intake accompanied by a calorie deficit can lead to macro/micronutrient deficiencies and loss of LM [59,63,73,152].”
Gigliotti, L., Warshaw, H., Evert, A., Dawkins, C., Schwartz, J., Susie, C., Kushner, R., Subramanian, S., Handu, D., & Rozga, M. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.10.023 · Cited by 53
Proportion of caloric restriction‐induced weight loss as skeletal muscle
Heymsfield, S. B., Yang, S., McCarthy, C., Brown, J. B., Martin, C. K., Redman, L. M., Ravussin, E., Shen, W., Müller, M. J., & Bosy‐Westphal, A. (2024) · Obesity · doi:10.1002/oby.23910 · Cited by 53
Jung, H. N., Kim, S.-O., Jung, C. H., Lee, W. J., Kim, M. J., & Cho, Y. K. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06796-9 · Cited by 51
Tirzepatide suppresses palatable food intake by selectively reducing preference for fat in rodents
Geisler, C. E., Antonellis, M. P., Trumbauer, W., Martin, J. A., Coskun, T., Samms, R. J., & Hayes, M. R. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14843 · Cited by 51
Herrou, J., Mabilleau, G., Lecerf, J.-M., Thomas, T., Biver, E., & Paccou, J. (2023) · Calcified Tissue International · doi:10.1007/s00223-023-01150-8 · Cited by 50
Caruso, I., Di Gioia, L., Di Molfetta, S., Caporusso, M., Cignarelli, A., Sorice, G. P., Laviola, L., & Giorgino, F. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02441-z · Cited by 49 · cited 1×
“…from the FDA Adverse Event Reporting System indicate a lower incidence of nausea and vomiting, potentially due to GIP receptor-mediated neuronal inhibition in the area postrema [149,150], whereas constipation appears more frequent, with the underlying mechanisms yet to be fully elucidated [151].”
Cavallo, M., Morgana, G., Dozzani, I., Gatti, A., Vandoni, M., Pippi, R., Pucci, G., Vaudo, G., & Fanelli, C. G. (2023) · Nutrients · doi:10.3390/nu15153473 · Cited by 48
Self-citationResistance Training in Post-Metabolic and Bariatric Surgery Patients: A Systematic Review
Morales-Marroquin, E., Kohl, H. W., Knell, G., de la Cruz-Muñoz, N., & Messiah, S. E. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04837-1 · Cited by 48 · cited 1×
“Lacking a definitive guideline for PA in post-BS, emerging evidence of the important role of resistance EXE has been found [53].”
Haghighat, N., Kazemi, A., Asbaghi, O., Jafarian, F., Moeinvaziri, N., Hosseini, B., & Amini, M. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2020.10.001 · Cited by 47 · cited 1×
“…loss: minimizing the amount of FFM loss, due to its detrimental consequences, is challenging for clinicians, especially after BS. Haghighat et al. [44] analyzed how different types of BS affect body composition in a period of at least one year after BD: Roux-en-Y-Gastric Bypass (RYGB) reduced FM…”
Incretin Hormones, Obesity and Gut Microbiota
Angelini, G., Russo, S., & Mingrone, G. (2024) · Peptides · doi:10.1016/j.peptides.2024.171216 · Cited by 47
Effect of Bimagrumab on Body Composition: A Systematic Review and Meta-Analysis
Kanbay, M., Siriopol, D., Copur, S., Hasbal, N. B., Güldan, M., Kalantar-Zadeh, K., Garfias-Veitl, T., & von Haehling, S. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02825-4 · Cited by 45 · cited 1×
“Phase 1 and 2 trials showed that bimagrumab treatment significantly increased FFM and was also effective in reducing FM [154].”
Integrating diet and physical activity when prescribing GLP-1s—Lifestyle factors remain crucial
Mehrtash, F., Dushay, J., & Manson, J. E. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.1794 · Cited by 44
Dietary supplements for obesity
Bonetti, G., Herbst, K. L., Donato, K., Dhuli, K., Kiani, A. K., Aquilanti, B., Velluti, V., Matera, G., Iaconelli, A., & Bertelli, M. (2022) · Journal of preventive medicine and hygiene · doi:10.15167/2421-4248/jpmh2022.63.2s3.2757 · Cited by 44
Dekker, I. M., van Rijssen, N. M., Verreijen, A., Weijs, P. J., de Boer, W. B. (., Terpstra, D., & Kruizenga, H. M. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.01.014 · Cited by 40
Romeijn, M. M., Holthuijsen, D. D. B., Kolen, A. M., Janssen, L., Schep, G., van Dielen, F. M. H., & Leclercq, W. K. G. (2021) · Nutrition Journal · doi:10.1186/s12937-021-00688-3 · Cited by 40
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Ryan, D. H. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09967-4 · Cited by 34 · cited 1×
“In these patients, excessive loss of LM, particularly muscle mass, is crucial because it increases the risk of frailty, falls, and fractures [123,124].”
Camajani, E., Persichetti, A., Watanabe, M., Contini, S., Vari, M., Di Bernardo, S., Faro, M., Lubrano, C., Gnessi, L., Caprio, M., et al. (2022) · Nutrients · doi:10.3390/nu14091884 · Cited by 34 · cited 2×
“Consequent reduction in magnesium in the liver increases NAPDH levels and promotes triglycerides and very low-density lipoprotein synthesis, facilitating obesity [91].”
Nederveen, J. P., Mastrolonardo, A. J., Xhuti, D., Di Carlo, A., Manta, K., Fuda, M. R., & Tarnopolsky, M. A. (2023) · Nutrients · doi:10.3390/nu15173693 · Cited by 33
Boppre, G., Diniz‐Sousa, F., Veras, L., de Oliveira, J. J. F., & Fonseca, H. (2021) · Obesity Science & Practice · doi:10.1002/osp4.542 · Cited by 33
Treating sarcopenic obesity in the era of incretin therapies: perspectives and challenges
Chen, A. S., & Batsis, J. A. (2025) · Diabetes · doi:10.2337/dbi25-0004 · Cited by 32 · cited 3×
“Strength training and other strategies to preserve lean body mass are likely to be particularly important in patients using AOMs, as well as in older adults who may have SO [121,122].”
Zinc homeostasis and redox alterations in obesity
Franco, C., & Canzoniero, L. M. T. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1273177 · Cited by 31
Rondanelli, M., Miraglia, N., Putignano, P., Castagliuolo, I., Brun, P., Dall’Acqua, S., Peroni, G., Faliva, M. A., Naso, M., Nichetti, M., et al. (2021) · Nutrients · doi:10.3390/nu13082512 · Cited by 31
Physical activity in the new era of antiobesity medications
Jakicic, J. M., Rogers, R. J., & Church, T. S. (2024) · Obesity · doi:10.1002/oby.23930 · Cited by 30
Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary?
Chavez, A. M., Barria, R. C., & León-Sanz, M. (2025) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001130 · Cited by 30
Jun, L., Tao, Y.-X., Geetha, T., & Babu, J. R. (2024) · Current Nutrition Reports · doi:10.1007/s13668-024-00555-7 · Cited by 27
Fadini, G. P., Bonora, B. M., Ghiani, M., Anichini, R., Melchionda, E., Fattor, B., Fazion, S., Meregalli, G., Giaccari, A., Avogaro, A., et al. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15554 · Cited by 27
Deng, F., Wu, W., Fan, X., Zhong, X., Wang, N., Wang, Y., Pan, T., & Du, Y. (2023) · International Journal of Endocrinology · doi:10.1155/2023/9926462 · Cited by 26 · cited 1×
“This occurs despite preclinical evidence suggesting that these agents may exert beneficial effects on skeletal muscle by mitigating obesity-related muscle atrophy, modulating inflammation, and improving muscle fiber composition, size, and lipid distribution [10,11].”
Durey, B. J., Fritche, D., Martin, D. S., & Best, L. M. J. (2022) · Obesity Surgery · doi:10.1007/s11695-021-05743-w · Cited by 26 · cited 1×
“…be helpful both in educational terms (leading obese people to the consciousness of the importance of changing lifestyle) and in post-surgical outcomes (i.e., percentage of WL, muscle strength, and cardiorespiratory fitness (CRF) expressed in VO2 max, even if this evidence is not so robust [51].”
Adipose Tissue Dysfunction and Metabolic Diseases: The Role of Vitamin D/Vitamin D Receptor Axis
Cimini, F. A., Sentinelli, F., Oldani, A., Barchetta, I., & Cavallo, M. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110256 · Cited by 26
Self-citationMalnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF
DRIGGIN, E., & GOYAL, P. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.01.005 · Cited by 24
Dash, S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15829 · Cited by 24
Using Gut Microbiota Modulation as a Precision Strategy Against Obesity
Baek, K.-R., Singh, S., Hwang, H.-S., & Seo, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136282 · Cited by 24
Weight Loss and Body Composition after Compounded Semaglutide Treatment in a Real World Setting
Chun, E., Siojo, A., Rivera, D., Reyna, K., Legere, H., Joseph, R., & Pojednic, R. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16162 · Cited by 23
Bobe, G., Michels, A. J., Zhang, W.-J., Purnell, J. Q., Woffendin, C., Pereira, C., Vita, J. A., Thomas, N. O., Traber, M. G., Frei, B., et al. (2020) · The Journal of Nutrition · doi:10.1093/jn/nxaa203 · Cited by 22 · cited 2×
“Bobe G. et al. [106] N: 81 Mean age: 39 ± 9 yrs Mean BMI = 34.6 ± 6.1 (kg/m 2 ) 600 mg/d of (R)- α -lipoic acid (R-LA) supplementation vs. placebo Duration: 24 weeks The R-LA group had a greater BMI reduction than the placebo at 24 weeks ( − 0.8; p = 0.04).”
InfluentialExercise Training Does Improve Cardiorespiratory Fitness in Post-Bariatric Surgery Patients
da Silva, A. L. G., Sardeli, A. V., André, L. D., Severin, R., de Oliveira, C. R., Hassan, C., Borghi-Silva, A., & Phillips, S. A. (2019) · Obesity Surgery · doi:10.1007/s11695-019-03731-9 · Cited by 20
Ağagündüz, D., Acar-Tek, N., & Bozkurt, O. (2021) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2021/7809611 · Cited by 20 · cited 2×
“…in terms of WL and improved metabolic parameters are significant, their influence on eating patterns and dietary quality has not been widely reported, and an unbalanced nutritional intake accompanied by a calorie deficit can lead to macro/micronutrient deficiencies and loss of LM [59,63,73,152].”
Roles of Amino Acid Derivatives in the Regulation of Obesity
Zheng, J., Xiao, H., Duan, Y., Song, B., Zheng, C., Guo, Q., Li, F., & Li, T. (2021) · Food & Function · doi:10.1039/d1fo00780g · Cited by 20 · cited 1×
“The mechanisms underlying the effects of these amino acid derivatives primarily involve the inhibition of adipogenesis, stimulation of lipolysis, promotion of brown and beige adipose tissue development, and enhancement of glucose metabolism [103].”
I am taking a GLP-1 weight-loss medication—What should I know
Mehrtash, F., Dushay, J., & Manson, J. E. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.1133 · Cited by 19
Medical Nutrition Therapy: Still Relevant in the Era of Pharmacotherapy for Obesity Care
Miller, C. K. (2025) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2024.06.222 · Cited by 19 · cited 2×
“…in terms of WL and improved metabolic parameters are significant, their influence on eating patterns and dietary quality has not been widely reported, and an unbalanced nutritional intake accompanied by a calorie deficit can lead to macro/micronutrient deficiencies and loss of LM [59,63,73,152].”
InfluentialSchmidt, P. H. S., Pasqualotto, E., dos Santos, H. V., de Souza, L. S. N., dos Santos, B. E., Chavez, M. P., Ferreira, R. O. M., Hohl, A., Ronsoni, M. F., & van de Sande-Lee, S. (2025) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.009 · Cited by 18 · cited 1×
“In contrast, a more recent systematic review encompassing 15 studies with 960 individuals confirmed significant reductions in body weight, FM, and visceral AT compared with placebo, while indicating inconsistent effects on LM [35].”
Wu, W., Chen, Z., Han, J., Qian, L., Wang, W., Lei, J., & Wang, H. (2023) · Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity · doi:10.1007/s40519-023-01593-w · Cited by 18 · cited 2×
“Since obesity is a complex and multifactorial condition influenced by modern lifestyle, alterations in the gut microbiota, epigenetic, and hormonal factors [107], there has been growing interest in the use of postbiotics (metabolites produced by probiotics) as a potential therapeutic approach [108].”
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25168650 · Cited by 17 · cited 1×
“Through these mechanisms, incretin-based medications promote body weight reduction primarily by targeting AT [6].”
Al-Najim, W., Raposo, A., BinMowyna, M. N., & le Roux, C. W. (2025) · Nutrients · doi:10.3390/nu17111934 · Cited by 16 · cited 1×
“Symptoms such as reduced appetite, early satiety, and nausea may limit dietary variety and protein intake, leading to muscle loss [63–65].”
Effects of Acute Exercise on Pancreatic Endocrine Function in Subjects with Type 2 Diabetes
Knudsen, S. H., Karstoft, K., Winding, K., Holst, J. J., Pedersen, B. K., & Solomon, T. P. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12413 · Cited by 15 · cited 2×
“Knudsen [134] et al. observed that a 1 h treadmill walk at 65% of peak heart rate in the morning increased beta-cell sensitivity to GLP-1.”
Endurance Training Improves GLP-1 Sensitivity and Glucose Tolerance in Overweight Women
Åkerström, T., Stolpe, M. N., Widmer, R., Dejgaard, T. F., Højberg, J. M., Møller, K., Hansen, J. S., Trinh, B., Holst, J. J., Thomsen, C., et al. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac111 · Cited by 15
Fitch, A., Gigliotti, L., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100205 · Cited by 14 · cited 3×
“The quality and type of diet during drug treatment with AOMs are crucial for the patient’s nutritional status, especially in the long term [67].”
InfluentialAdipose Tissue Dysfunction and Metabolic Diseases: The Role of Vitamin D/Vitamin D Receptor Axis
Cimini, F. A., Sentinelli, F., Oldani, A., Barchetta, I., & Cavallo, M. G. (2025) · doi:10.20944/preprints202509.1434.v1 · Cited by 14
Self-citationGWIN, J. A., CHURCH, D. D., ALLEN, J. T., WILSON, M. A., CARRIGAN, C. T., MURPHY, N. E., VARANOSKE, A. N., MARGOLIS, L. M., WOLFE, R. R., FERRANDO, A. A., et al. (2025) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000003541 · Cited by 12
Exercise for Clients Taking an Anti-Obesity Medication
Rogers, R. J. (2024) · ACSM'S Health & Fitness Journal · doi:10.1249/fit.0000000000000959 · Cited by 12
Stokic, E., Romani, A., Ilincic, B., Kupusinac, A., Stosic, Z., & Isenovic, E. R. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161115666170821154841 · Cited by 11
Kang, M., Rho, H., Kim, M., Lee, M., Lim, Y., Chon, J., & Lim, H. (2025) · The Journal of nutrition, health and aging · doi:10.1016/j.jnha.2025.100508 · Cited by 10
Daily Timing of Meals and Weight Loss After Bariatric Surgery: A Systematic Review
Cossec, M., Atger, F., Blanchard, C., & Jacobi, D. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05278-0 · Cited by 9
Abiri, B., Valizadeh, M., Seifi, Z., Amini, S., & Haidari, F. (2025) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-025-01761-0 · Cited by 9
Brunani, A., Cancello, R., Gobbi, M., Lucchetti, E., Di Guglielmo, G., Maestrini, S., Cattaldo, S., Piterà, P., Ruocco, C., Milesi, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134257 · Cited by 8 · cited 1×
“Furthermore, under conditions of calorie restriction, it appears to be beneficial to supplement the daily protein intake with Essential Amino Acids (EAAS) [86], especially to enhance the post-exercise anabolic effect, which would otherwise not be stimulated by the deficit itself [87].”
Is There Sustained Weight Loss after Discontinuation of GLP-1 Agonist for Obesity Treatment?
Caro, R., Samsel, D., & Savel, P. (2023) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001786 · Cited by 7 · cited 1×
“The effects of GLP-1 RAs on weight reduction are dose-and duration-dependent [127].”
Bond, D. S., Wu, Y., Baillot, A., Lillis, J., Sundgot-Borgen, C., & Papasavas, P. K. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00658-4 · Cited by 6 · cited 1×
“Independent of the characteristics of PA after BS, it could enhance weight loss, muscle strength, and CRF [54–56].”
The Sweet Side of Constipation: Colonic Motor Dysfunction in Diabetes Mellitus
De Fano, M., Baluganti, S., Manco, M., Porcellati, F., Fanelli, C. G., & Bassotti, G. (2025) · Nutrients · doi:10.3390/nu17193038 · Cited by 4 · cited 1×
“…from the FDA Adverse Event Reporting System indicate a lower incidence of nausea and vomiting, potentially due to GIP receptor-mediated neuronal inhibition in the area postrema [149,150], whereas constipation appears more frequent, with the underlying mechanisms yet to be fully elucidated [151].”
Self-citationNew Drugs for Obesity, Is the Excitement Affordable?
Duncan, I., Kerr, D., Aggarwal, R., & Huynh, N. (2023) · Population Health Management · doi:10.1089/pop.2023.0086 · Cited by 4
“Strength gains in different age groups of overweight/obese adults: A pilot uncontrolled study”
Pippi, R., Moretti, L., Carnevali, C., Tingoli, L., Settequattrini, A., Fatone, C., Perrone, C., Reginato, E., Feo, P. D., & Fanelli, C. G. (2022) · Cogent Social Sciences · doi:10.1080/23311886.2022.2106645 · Cited by 2
Self-citationSevere Hypomagnesemia and Hypocalcemia Linked to Semaglutide in Type 2 Diabetes: A Case Report
Davis, T. M. E. (2024) · American Journal of Case Reports · doi:10.12659/ajcr.946539 · Cited by 2
A New Role for Glucagon: From Secondary Hormone to Key Player
De Fano, M., Malara, M., Rucco, S., Manco, M., Fanelli, C. G., Bolli, G. B., & Porcellati, F. (2025) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104233 · Cited by 1
Self-citation263-OR: Effects of Tirzepatide on Central Reward and Appetite Circuits in the Brain
CARMICHAEL, O., MARTIN, C. K., CONSIDINE, R. V., KAREKEN, D. A., CARNELL, S., DYDAK, U., MATTES, R. D., SCOTT, D., SVALDI, D. O., NISHIYAMA, H., et al. (2024) · Diabetes · doi:10.2337/db24-263-or · Cited by 1
Cited by
Al-Awadi, A. A., Alroudhan, D., Alsaeed, D., Almarshad, B. W., Alshehabi, D. H., Al‐Lahou, B., Mashankar, A., Al‐Ozairi, E., & Gray, S. (2026) · BMJ Open · doi:10.1136/bmjopen-2026-116911 · Cited by 16
Zambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 8
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
“Recent GLP-1-specific narrative consensus extends these recommendations to patients receiving incretin-based pharmacotherapy [71].”
Olumuyide, E. O., Ariel, K., & Aneni, E. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02143-x · Cited by 1
Mallardo, M., Messina, A., Monda, V., Marra, M. L., Monda, A., Allocca, S., Casillo, M., Maio, G. D., Perrone, P., Daniele, A., et al. (2026) · Nutrients · doi:10.3390/nu18172748 · Cited by 1
Metadata
- Authors
- Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R.
- Affiliations
- Ospedale degli Infermi (IT)
- Endocrine and Metabolic Sciences Section, Department of Medicine and Surgery, University of Perugia, 06132 Perugia, Italy
- Azienda Ospedaliera S.Maria (IT)
- University of Perugia (IT)
- Corresponding author
- Cavallo, Massimiliano
- Prete, Deborah
- ORCID
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2025-12-31
- Volume
- 18
- Issue
- 1
- Pages
- 131
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC12787956
- OpenAlex
- W7117762628
- Cited by
- 13
- References
- 144
- Citations by year
- 2026: 13
- FWCI
- 1.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- obesity, weight loss, lean mass preservation, muscle mass loss, bone loss, malnutrition, protein supplementation, hypocaloric diet, amino acid supplementation, vitamin and mineral supplementation, physical activity, resistance training, gut microbiota, adipose tissue reduction, weight maintenance
- MeSH terms
- Body Composition, Humans, Obesity, Weight Loss, Exercise, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
